Evidence map›Paper›PMID 29246156›Full record

ArticleMicrobial cell factories2017

The tunable pReX expression vector enables optimizing the T7-based production of membrane and secretory proteins in E. coli.

Grietje Kuipers, Alexandros Karyolaimos, Zhe Zhang, Nurzian Ismail, Gianluca Trinco, David Vikström, Dirk Jan Slotboom, Jan-Willem de Gier

Open access · goldAbstract read
In one paragraph

Article in Microbial cell factories, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Plasmids for Controlled and Tunable High-Level Expression in E. coli.Applied and environmental microbiology · 2022
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Grietje KuipersDepartment of Biochemistry and Biophysics, Center for Biomembrane Research, Stockholm University, SE-106 91, Stockholm, Sweden.
Alexandros KaryolaimosDepartment of Biochemistry and Biophysics, Center for Biomembrane Research, Stockholm University, SE-106 91, Stockholm, Sweden.
Zhe ZhangDepartment of Biochemistry and Biophysics, Center for Biomembrane Research, Stockholm University, SE-106 91, Stockholm, Sweden.
Nurzian IsmailXbrane Biopharma AB, SE-111 45, Stockholm, Sweden.
Gianluca TrincoUniversity of Groningen, Groningen Biomolecular Sciences and Biotechnology Institute, NL-9747 AG, Groningen, The Netherlands.
David VikströmXbrane Biopharma AB, SE-111 45, Stockholm, Sweden.
Dirk Jan SlotboomUniversity of Groningen, Groningen Biomolecular Sciences and Biotechnology Institute, NL-9747 AG, Groningen, The Netherlands.
Jan-Willem de GierDepartment of Biochemistry and Biophysics, Center for Biomembrane Research, Stockholm University, SE-106 91, Stockholm, Sweden. degier@dbb.su.se.ORCID http://orcid.org/0000-0001-5537-4358
Stockholm University · SEUniversity of Groningen · NLXbrane Biopharma (Sweden) · SE

Funding

Marie Curie Initial Training Network grant FP7-PEOPLE-2013-ITN, TAMPting, 607072Marie Curie Initial Training Network grant Horizon 2020, ProteinFactory, 642863
6 · The paper itself

Abstract

backgroundTo optimize the production of membrane and secretory proteins in Escherichia coli, it is critical to harmonize the expression rates of the genes encoding these proteins with the capacity of their biogenesis machineries. Therefore, we engineered the Lemo21(DE3) strain, which is derived from the T7 RNA polymerase-based BL21(DE3) protein production strain. In Lemo21(DE3), the T7 RNA polymerase activity can be modulated by the controlled co-production of its natural inhibitor T7 lysozyme. This setup enables to precisely tune target gene expression rates in Lemo21(DE3). The t7lys gene is expressed from the pLemo plasmid using the titratable rhamnose promoter. A disadvantage of the Lemo21(DE3) setup is that the system is based on two plasmids, a T7 expression vector and pLemo. The aim of this study was to simplify the Lemo21(DE3) setup by incorporating the key elements of pLemo in a standard T7-based expression vector.

resultsBy incorporating the gene encoding the T7 lysozyme under control of the rhamnose promoter in a standard T7-based expression vector, pReX was created (ReX stands for Regulated gene eXpression). For two model membrane proteins and a model secretory protein we show that the optimized production yields obtained with the pReX expression vector in BL21(DE3) are similar to the ones obtained with Lemo21(DE3) using a standard T7 expression vector. For another secretory protein, a c-type cytochrome, we show that pReX, in contrast to Lemo21(DE3), enables the use of a helper plasmid that is required for the maturation and hence the production of this heme c protein.

conclusionsHere, we created pReX, a T7-based expression vector that contains the gene encoding the T7 lysozyme under control of the rhamnose promoter. pReX enables regulated T7-based target gene expression using only one plasmid. We show that with pReX the production of membrane and secretory proteins can be readily optimized. Importantly, pReX facilitates the use of helper plasmids. Furthermore, the use of pReX is not restricted to BL21(DE3), but it can in principle be used in any T7 RNAP-based strain. Thus, pReX is a versatile alternative to Lemo21(DE3).

Indexed as

Gene ExpressionCloning, MolecularDNA-Directed RNA PolymerasesEscherichia coliGenetic VectorsMembrane ProteinsN-Acetylmuramoyl-L-alanine AmidasePlasmidsPromoter Regions, GeneticProtein TransportViral Proteinsbacteriophage T7 RNA polymeraseDNA-Directed RNA PolymerasesMembrane ProteinsN-Acetylmuramoyl-L-alanine AmidaseViral ProteinsEscherichia coliLemo21(DE3)Membrane proteinProtein productionSecretory proteinT7 RNA polymerase

Identifiers

PMID29246156
PMCPMC5732464
OpenAlexW2774227215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.